Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Solvency Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Johnson & Johnson, P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 14, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Johnson & Johnson Annual Report.
- Share Price Trends
- The share price exhibited an overall upward trajectory from 59.29 USD in March 2006 to a peak of 166.19 USD in February 2022, reflecting sustained growth over the period. Some fluctuations are noticeable, such as a decline from 65 USD in February 2007 to 54.65 USD in February 2009, followed by a recovery phase. Post-2022, a slight decrease is observed through February 2024, with prices stabilizing near 156-158 USD before a minor rise to 157.25 USD in February 2025. This pattern suggests volatility in recent years but a long-term positive performance.
- Earnings per Share (EPS) Trends
- EPS displayed considerable variability throughout the period. Starting at 3.5 USD in 2006, it generally increased, reaching 5.87 USD in 2014 and peaking at 7.94 USD in February 2022. Anomalous data appears in February 2018, when EPS dropped sharply to 0.48 USD, followed by a rebound to 5.74 USD in 2019 and subsequent years. Another notable peak occurred in February 2024 with 14.59 USD, which then decreased to 5.84 USD by February 2025. Overall, EPS growth is evident, but with significant fluctuations possibly due to extraordinary items or accounting adjustments in specific years.
- Price to Earnings (P/E) Ratio Analysis
- The P/E ratio largely fluctuated during the analyzed years. Initial values ranged around 16-17, dipping to the lowest point of 11.67 in 2009, correlating with the low share price at the time. A significant spike is seen in February 2018, when the P/E ratio soared to 268.1, coinciding with the extraordinary dip in EPS. This suggests an earnings anomaly or one-time event impacting reported profits. Following this, the ratio normalized between approximately 17 and 29 from 2019 to 2022, before dropping sharply to 10.73 in 2024, reflecting the exceptionally high EPS in that year, and rising again to 26.92 in February 2025. The P/E ratio’s volatility indicates periods of changing market expectations and earnings perceptions.
- Overall Insights
- The data reveals a general upward movement in share price and EPS over nearly two decades, signifying growth and value creation. However, the presence of irregular EPS values and corresponding P/E spikes suggests occasional extraordinary events affecting reported earnings. The recent stabilization of share price despite fluctuating earnings hints at potential market reassessment or external factors influencing investor sentiment. Continuous monitoring of earnings quality and market conditions is advisable to interpret future performance accurately.
Comparison to Competitors
Johnson & Johnson, P/E, long-term trends, comparison to competitors
| Johnson & Johnson | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | ||||||||||||
| Feb 16, 2024 | ||||||||||||
| Feb 16, 2023 | ||||||||||||
| Feb 17, 2022 | ||||||||||||
| Feb 22, 2021 | ||||||||||||
| Feb 18, 2020 | ||||||||||||
| Feb 20, 2019 | ||||||||||||
| Feb 21, 2018 | ||||||||||||
| Feb 27, 2017 | ||||||||||||
| Feb 24, 2016 | ||||||||||||
| Feb 24, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Feb 22, 2013 | ||||||||||||
| Feb 23, 2012 | ||||||||||||
| Feb 25, 2011 | ||||||||||||
| Mar 1, 2010 | ||||||||||||
| Feb 20, 2009 | ||||||||||||
| Feb 26, 2008 | ||||||||||||
| Feb 21, 2007 | ||||||||||||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Johnson & Johnson, P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Johnson & Johnson | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 16, 2024 | ||
| Feb 16, 2023 | ||
| Feb 17, 2022 | ||
| Feb 22, 2021 | ||
| Feb 18, 2020 | ||
| Feb 20, 2019 | ||
| Feb 21, 2018 | ||
| Feb 27, 2017 | ||
| Feb 24, 2016 | ||
| Feb 24, 2015 | ||
| Feb 21, 2014 | ||
| Feb 22, 2013 | ||
| Feb 23, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 20, 2009 | ||
| Feb 26, 2008 | ||
| Feb 21, 2007 | ||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Johnson & Johnson, P/E, long-term trends, comparison to industry (health care)
| Johnson & Johnson | Health Care | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 16, 2024 | ||
| Feb 16, 2023 | ||
| Feb 17, 2022 | ||
| Feb 22, 2021 | ||
| Feb 18, 2020 | ||
| Feb 20, 2019 | ||
| Feb 21, 2018 | ||
| Feb 27, 2017 | ||
| Feb 24, 2016 | ||
| Feb 24, 2015 | ||
| Feb 21, 2014 | ||
| Feb 22, 2013 | ||
| Feb 23, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 20, 2009 | ||
| Feb 26, 2008 | ||
| Feb 21, 2007 | ||
| Mar 14, 2006 |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).